Floatz logo

Metformin

Sarcopenic Obesity

VA Office of Research and DevelopmentSmall moleculePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Sarcopenic Obesity cohort.

Asset / SponsorPhaseRating
VITAMIN D
Fondazione Policlinico Universitario Campus Bio-Medico
Phase 4BB
Tirzepatide
Pennington Biomedical Research Center
Phase 4BB
imm01-stem
Immunis, Inc.
Phase 2CCC
Oxytocin
Sara Espinoza
Phase 1/2CCC
Iodixanol
Nemocnice AGEL Trinec-Podlesi a.s.
D

Same molecule, other indications

Metformin is also rated in:

Metabolism and Nutrition DisorderDormant
A
Indicative ·
82 / 100
View asset →
prediabetes syndromeDormant
A
Indicative ·
81 / 100
View asset →
gestational diabetesDormant
A
Indicative ·
81 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →